Tenaya Therapeutics, Inc.

Contributing Author

Recent Articles by Tenaya Therapeutics, Inc.

4 hours	Tenaya Therapeutics Announces Interim Data from MyPEAK-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms TNYA GlobeNewswire
Jun-02	Tenaya Therapeutics to Announce New Interim Data from MyPEAK-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026 TNYA -9.20% GlobeNewswire
May-29	Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026 TNYA +8.77% GlobeNewswire
May-15	Positive Interim Data from Cohorts 1 and 2 of Tenaya's RIDGE-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC TNYA -8.31% GlobeNewswire
May-06	Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update TNYA +7.37% TNYA GlobeNewswire
Apr-27	Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026 TNYA GlobeNewswire
Mar-11	Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update TNYA GlobeNewswire
Mar-09	Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301's Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy TNYA +7.84% GlobeNewswire
Mar-05	Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics TNYA +40.92% GlobeNewswire
Mar-02	Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026 TNYA GlobeNewswire
Jan-09	Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones TNYA GlobeNewswire
Dec-12	Tenaya Therapeutics Announces Pricing of Public Offering TNYA -37.50% GlobeNewswire
Dec-11	Tenaya Therapeutics Announces Proposed Public Offering TNYA GlobeNewswire
Dec-11	Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC TNYA -37.50% TNYA GlobeNewswire
Dec-11	Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy TNYA -37.50% TNYA GlobeNewswire
Nov-10	Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update TNYA +11.72% GlobeNewswire
Nov-08	Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy TNYA GlobeNewswire
Nov-04	Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025 TNYA GlobeNewswire
Oct-09	Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference TNYA +10.38% GlobeNewswire
Oct-02	Tenaya Therapeutics to Participate in Upcoming October Investor Conferences TNYA GlobeNewswire
Sep-18	Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) TNYA +8.20% TNYA +6.82% GlobeNewswire
Sep-02	Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference TNYA +9.26% TNYA GlobeNewswire
Aug-31	Tenaya Therapeutics Presents Interim Data from MyClimb Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025 TNYA GlobeNewswire
Aug-08	Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference TNYA GlobeNewswire
Aug-06	Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update TNYA GlobeNewswire
Jul-30	Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed TNYA GlobeNewswire
May-15	Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) TNYA GlobeNewswire
May-13	Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting TNYA GlobeNewswire
May-07	Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update TNYA GlobeNewswire

Tenaya Therapeutics, Inc.

Recent Articles by Tenaya Therapeutics, Inc.

Upgrade your Finviz experience